NCT00122265|TerminatedDMC
Loading search results
Sponsor study identifier
observational
83
1 country
1
Study Start
April 2003
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2012
Actual (reported)Study Completion
January 2012
Actual (reported)Prostate cancer is the most common malignancy in males, and radiotherapy is a commonly chosen treatment option for patients with localized disease. Technical innovations such as three-dimensional conformal radiotherapy (3D CRT) and intensity-modulated radiotherapy permit radiation dose escalation and possibly better disease outcomes, but escalated doses may be accompanied by long-term complications. This study will examine, for the first time, the independent contribution of a patient's own genetic makeup to the development of post-radiation complications, permitting the future development of predictive tests to avoid radiation injury. To do this, the investigators will examine gene markers and blood proteins in a series of approximately 100 prostate cancer survivors who have received three-dimensional conformal radiotherapy between 1996 and 2000 at the Cross Cancer Institute.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2012
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 2003
Date type not reportedThis date has not been verified as actual or estimated.
July 20, 2005
Actual (reported)July 22, 2005
Actual (reported)January 2012
Actual (reported)January 2012
Actual (reported)community sample
Contact the study team to confirm eligibility.
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
Matthew Parliament, MD
Cross Cancer Institute
83 participants (actual enrollment reported by the registry).
First Submitted
July 20, 2005
First Posted
July 22, 2005
Study Start
April 2003
Date type not reportedThis date has not been verified as actual or estimated.
Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer
Primary Completion
January 2012
Actual (reported)Study Completion
January 2012
Actual (reported)Last Updated
February 26, 2016
Record last verified: 2012-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: